资讯

TipRanks on MSN23 小时
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
Atea Pharmaceuticals (AVIR) announced that the first patient has been dosed in C-BEYOND, Atea’s Phase 3 trial evaluating the regimen of ...